Maitalon 20/21+7 (Drospirenone, Ethinylestradiol | Lactose Anhydrous)

• Maitalon 20/21+7, a combined oral contraceptive, is used to manage reproductive hormone‑related conditions.
• Contraception: provides reliable birth control by inhibiting ovulation and creating cervical mucus changes that reduce sperm penetration, suitable for women seeking a reversible, hormone‑based method.
• Menstrual cycle regulation: helps to establish a more predictable bleeding pattern, reduces dysmenorrhea and heavy menstrual bleeding, and can improve cycle‑related hormonal symptoms in women with irregular periods.
• Hormonal balance: assists in stabilizing estrogen‑progesterone fluctuations, which may alleviate premenstrual syndrome symptoms for some users.

• Drospirenone is a synthetic progestogen with anti‑mineralocorticoid and anti‑androgenic activity, while ethinylestradiol is a synthetic estrogen. Together they suppress the hypothalamic‑pituitary‑ovarian axis, preventing the mid‑cycle surge of luteinizing hormone and follicle‑stimulating hormone, thereby inhibiting ovulation. They also thicken cervical mucus and induce endometrial changes that reduce the likelihood of fertilisation and implantation. The combined formulation provides a steady hormonal level that mimics the natural menstrual cycle, supporting cycle control.

Maitalon 20/21+7 may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects

• Nausea
• Breast tenderness
• Headache
• Weight gain
• Spotting between periods
• Mood changes

Serious or Rare Side Effects

• Venous thromboembolism (deep‑vein thrombosis, pulmonary embolism)
• Arterial thrombosis (stroke, myocardial infarction)
• Severe hypertension
• Liver dysfunction or cholestasis
• Gallbladder disease
• Anaphylactic or severe allergic reactions

Before prescribing Maitalon 20/21+7, clinicians should evaluate patient‑specific risk factors and provide counseling on proper use.

• Assess cardiovascular risk: review personal and family history of thromboembolic events.
• Review smoking status: avoid use in women over 35 who smoke.
• Check liver function: contraindicated in severe hepatic impairment.
• Counsel on missed tablets: follow specific instructions to maintain efficacy.
• Avoid use during pregnancy: contraindicated due to teratogenic risk.
• Store at ambient temperature: keep in the original pack, protect from moisture.

Maitalon 20/21+7 can interact with several medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin) may markedly reduce contraceptive efficacy.
• St. John’s wort can decrease plasma hormone levels, increasing the risk of unintended pregnancy.
• Protease inhibitors (e.g., ritonavir) may lower contraceptive effectiveness.

Moderate Interactions (Monitor Closely)

• Antifungal agents such as ketoconazole may increase hormone concentrations, raising the chance of side effects.
• Certain antibiotics (macrolides, tetracyclines) have uncertain effects; monitor for breakthrough bleeding.
• Select antidepressants (SSRIs) may alter bleeding patterns and require observation.